๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Active Systemic Lupus Erythematosus

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care NCT07424261n/a21 sites๐Ÿ“ Altenburg๐Ÿ“ Bad Bramstedt๐Ÿ“ Bamberg AstraZeneca A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants NCT05039619Phase 244 sites๐Ÿ“ Loma Linda๐Ÿ“ San Francisco๐Ÿ“ Aurora Hoffmann-La Roche ยท Tests: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl) A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants NCT06576271Phase 128 sites๐Ÿ“ Scottsdale๐Ÿ“ Aurora๐Ÿ“ Las Vegas GlaxoSmithKline ยท Tests: GSK4527363, Placebo matching GSK4527363, Belimumab A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) NCT07311200Phase 21 site๐Ÿ“ Linfen InventisBio Co., Ltd ยท Tests: D-2570, D-2570 Placebo To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis NCT07629583Phase 12 sites๐Ÿ“ Toulouse๐Ÿ“ Seville Genentech, Inc. ยท Tests: Cevostamab, Tocilizumab A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus NCT06106906Phase 1, Phase 21 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CD19 CAR-T cell infusion A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus NCT06617325Phase 3242 sites๐Ÿ“ Avondale๐Ÿ“ Chandler๐Ÿ“ Gilbert UCB Biopharma SRL ยท Tests: DZP, Placebo Effects of High-intensity Interval Training in Patients With Systemic Lupus Erythematosus NCT06166199NA1 site๐Ÿ“ Stockholm Karolinska Institutet ยท Tests: HIIT combined with resistance training Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients NCT06394063NA1 site๐Ÿ“ Shanghai RenJi Hospital ยท Tests: Telitacicept, Placebo A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus NCT07260877Phase 234 sites๐Ÿ“ Beverly Hills๐Ÿ“ Clearwater๐Ÿ“ DeBary Ventus Therapeutics U.S., Inc. ยท Tests: VENT-03, Placebo A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) NCT07355218Phase 357 sites๐Ÿ“ Upland๐Ÿ“ DeBary๐Ÿ“ Fort Lauderdale EMD Serono Research & Development Institute, Inc. ยท Tests: Enpatoran, Placebo, Standard of care (SoC) A Clinical Study of CD19 Universal CAR-ฮณฮดT Cells in Active Systemic Lupus Erythematosus NCT06106893Phase 1, Phase 21 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CD19 Universal CAR-ฮณฮด T Cells An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) NCT07617740EARLY Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: IASO207 Injection Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. NCT07330245n/a22 sites๐Ÿ“ Monserrato๐Ÿ“ Cona๐Ÿ“ San Giovanni Rotondo AstraZeneca ยท Tests: Anifrolumab Dose Response of Exercise for Arthritis Management NCT06880653NA1 site๐Ÿ“ Columbia University of South Carolina ยท Tests: DREAM Adaptive Intervention A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) NCT07491900Phase 11 site๐Ÿ“ Brisbane Hinge Bio ยท Tests: HB2198 Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients NCT07215754n/a1 site๐Ÿ“ Pisa University of Pisa Clinical Study of Cizutamig in Systemic Lupus Erythematosus NCT07215663Phase 117 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Candid Therapeutics ยท Tests: Cizutamig UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis NCT07109986Phase 11 site๐Ÿ“ Nanjing Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV410 A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis NCT07598396Phase 224 sites๐Ÿ“ CABA๐Ÿ“ Buenos Aires๐Ÿ“ Salvador Hoffmann-La Roche ยท Tests: Mosunetuzumab Dapagliflozin in Active Lupus Nephritis NCT07323524Phase 42 sites๐Ÿ“ Boston๐Ÿ“ Boston Brigham and Women's Hospital ยท Tests: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and โ‰ฅ2 Immunosuppressants NCT07175285n/a66 sites๐Ÿ“ La Jolla๐Ÿ“ La Palma๐Ÿ“ Los Angeles Bristol-Myers Squibb ยท Tests: Current standard of care treatment options RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus NCT06121297Phase 1, Phase 223 sites๐Ÿ“ Orange๐Ÿ“ Sacramento๐Ÿ“ New Haven Cabaletta Bio ยท Tests: CABA-201, CABA-201 A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus NCT06535412Phase 1, Phase 21 site๐Ÿ“ Beijing ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. ยท Tests: IMC-002 + SOC, Placebo + SOC, IMM0306S + SOC Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients NCT06631404n/a1 site๐Ÿ“ Sohag Sohag University ยท Tests: renal doppler VIBRANT: VIB4920 for Active Lupus Nephritis NCT05201469Phase 217 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Orange National Institute of Allergy and Infectious Diseases (NIAIโ€ฆ ยท Tests: VIB4920, Placebo for VIB4920 A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus NCT07694336Phase 21 site๐Ÿ“ Philadelphia Victoria Werth ยท Tests: Quinacrine Hydrochloride, Placebo Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus NCT06400537Phase 12 sites๐Ÿ“ Wuhan๐Ÿ“ Taiyuan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: A-319 Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus NCT07881120Phase 2, Phase 33 sites๐Ÿ“ San Diego๐Ÿ“ DeBary๐Ÿ“ Missoula Beeline Medicines Corporation ยท Tests: Afimetoran, Placebo
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy